Erratum to “Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient”

[1]  E. Kaempgen,et al.  Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers , 2015, Cancer Immunology Research.

[2]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[3]  A. Bergquist,et al.  Epidemiology of cholangiocarcinoma. , 2015, Best practice & research. Clinical gastroenterology.

[4]  Y. Akagi,et al.  Personalized peptide vaccination for advanced colorectal cancer , 2015, Oncoimmunology.

[5]  S. H. van der Burg,et al.  Cryopreservation of MHC Multimers: Recommendations for Quality Assurance in Detection of Antigen Specific T Cells , 2014, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[6]  Hans-Georg Rammensee,et al.  HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL) , 2014, Proceedings of the National Academy of Sciences.

[7]  Nansheng Chen,et al.  Mutational landscape of intrahepatic cholangiocarcinoma , 2014, Nature Communications.

[8]  Benjamin Schubert,et al.  OptiType: precision HLA typing from next-generation sequencing data , 2014, Bioinform..

[9]  T. Pawlik,et al.  Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. , 2014, JAMA surgery.

[10]  E. J. White,et al.  Inflammatory Adverse Events are Associated with Disease-Free Survival after Vaccine Therapy among Patients with Melanoma , 2014, Annals of Surgical Oncology.

[11]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[12]  T. Pawlik,et al.  Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas , 2013, Nature Genetics.

[13]  K. Nathanson,et al.  Immunotherapy at Large: The road to personalized cancer vaccines , 2013, Nature Medicine.

[14]  L. Monasta,et al.  Cytokine Levels in the Serum of Healthy Subjects , 2013, Mediators of inflammation.

[15]  K. Hess,et al.  Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials , 2013, Oncotarget.

[16]  S. Stevanović,et al.  Biochemical large-scale identification of MHC class I ligands. , 2013, Methods in molecular biology.

[17]  Hiroaki Tanaka,et al.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.

[18]  H. Rammensee,et al.  Promiscuous survivin peptide induces robust CD4+ T‐cell responses in the majority of vaccinated cancer patients , 2012, International journal of cancer.

[19]  L. Amon,et al.  Treatment Failure of a TLR-7 Agonist Occurs Due to Self-Regulation of Acute Inflammation and Can Be Overcome by IL-10 Blockade , 2010, The Journal of Immunology.

[20]  R. Vermeulen,et al.  Reproducibility and Correlations of Multiplex Cytokine Levels in Asymptomatic Persons , 2008, Cancer Epidemiology Biomarkers & Prevention.

[21]  H. Rammensee,et al.  Matrilysin (MMP-7) Is a Novel Broadly Expressed Tumor Antigen Recognized by Antigen-Specific T Cells , 2008, Clinical Cancer Research.

[22]  H. Rammensee,et al.  Identification and Characterization of T-Cell Epitopes Deduced from RGS5, a Novel Broadly Expressed Tumor Antigen , 2007, Clinical Cancer Research.

[23]  H. Rammensee,et al.  Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas , 2006, Clinical Cancer Research.

[24]  H. Rammensee,et al.  Identification of a naturally processed cyclin D1 T‐helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry , 2004, European journal of immunology.

[25]  F. Miura,et al.  Aggressive Surgical Resection for Hilar-invasive and Peripheral Intrahepatic Cholangiocarcinoma , 2003, World Journal of Surgery.

[26]  M. Rijn,et al.  Hep Par 1 Antibody Stain for the Differential Diagnosis of Hepatocellular Carcinoma: 676 Tumors Tested Using Tissue Microarrays and Conventional Tissue Sections , 2003, Modern Pathology.

[27]  K. Takasaki,et al.  Extended resection for intrahepatic cholangiocarcinoma in Japan. , 1999, Journal of hepato-biliary-pancreatic surgery.